Cyclotriazadisulfonamide

环三氮杂二磺酰胺

Cyclotriazadisulfonamide

C655881-1ml

1ml

10mM in DMSO

-80℃储存

超低温冰袋运输

Cyclotriazadisulfonamide (CADA) is a specific CD4 -targeted HIV entry inhibitors. Cyclotriazadisulfonamide (CADA) inhibits the co-translational translocation of human CD4 (huCD4) into the ER lumen in a signal peptide (SP)-dependent way. Cyclotriazadisulfonamide is also a Sec61 translocon inhibitor In Vitro Cyclotriazadisulfonamide (CADA) significantly decreases the amount of cell surface CD4 -the main receptor for HIV -without altering the expression of any other cellular receptor examined so far. Cyclotriazadisulfonamide (CADA) exhibits an EC 50 of 0.4 μg/mL for CD4 in MO-DC cells. Treatment of MO-DC with 10 μg/mL of CADA results in 83% downregulation of cell surface CD4, an effect that is similar to that observed for CADA treatment of CD4 + T cells. CADA prevents MT-4 cells from HIV-1 and SIV infection (EC 50 are 0.7 and 1.2 g/ml, respectively). Cyclotriazadisulfonamide is a Sec61 translocon inhibitor with a selective nature. A proteomics study on T-cells is performed and identified only five substrates (huCD4, SORT, CD137, DNAJC3, PTK7, ERLEC1) for Cyclotriazadisulfonamide, with IC 50 s of 0.2–2 µM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: MO-DCs. Concentration: 0.4 μg/mL. Incubation Time: 24 h. Result: A 50% reduction in CD4 expression was obtained. IC50& Target:HIV-1

环三唑二磺酰胺（CADA）是一种特异性 CD4 靶向 HIV 进入抑制剂。环三唑二磺酰胺（CADA）以信号肽（SP）依赖的方式抑制人类 CD4（huCD4）向 ER 腔的共翻译转位。环三唑二磺酰胺

182316-44-5(DMSO)

C31H39N3O4S2

581.79 g/mol

O=S(N1CC(CN(S(=O)(C2=CC=C(C)C=C2)=O)CCCN(CC3=CC=CC=C3)CCC1)=C)(C4=CC=C(C)C=C4)=O